What Is SYX-5219 Oral Capsule?
SYX-5219 Oral Capsule is an investigational drug currently being studied in clinical trials. It is designed as an oral capsule, meaning it is taken by mouth. While the specific way SYX-5219 works in the body is not detailed in the available trial descriptions, it is being developed to treat certain medical conditions. The drug is currently under investigation for its potential use in treating Moderate to Severe Atopic Dermatitis.
Atopic dermatitis is a chronic inflammatory skin condition characterized by dry, itchy skin, rashes, and inflammation. SYX-5219 Oral Capsule aims to address the underlying mechanisms of this condition, though its precise therapeutic action is still being evaluated. It is currently being studied in a single clinical trial involving 149 participants, which began on April 30, 2026. This research is sponsored by Sitryx Therapeutics Ltd.
As an investigational drug, SYX-5219 Oral Capsule is not yet approved by regulatory bodies for any medical use. Its safety and effectiveness are being rigorously assessed through ongoing clinical research.
Uses and Conditions Under Study
SYX-5219 Oral Capsule is currently being investigated for its potential to treat Moderate to Severe Atopic Dermatitis. Atopic dermatitis, often referred to as eczema, is a chronic inflammatory skin condition characterized by intense itching, dry skin, and recurring rashes. These symptoms can significantly affect a person's daily life, leading to sleep disturbances, discomfort, and emotional distress. Moderate to severe forms of the condition typically involve widespread skin involvement and more persistent symptoms, often requiring advanced treatment strategies.
The investigational SYX-5219 Oral Capsule is being studied to determine if it can effectively manage the symptoms and reduce the inflammation associated with this challenging condition. Researchers are evaluating whether the drug can provide meaningful relief for patients who suffer from moderate to severe atopic dermatitis, potentially offering a new oral treatment option.
Currently, SYX-5219 Oral Capsule is being evaluated in one clinical trial, which is specifically focused on Moderate to Severe Atopic Dermatitis. This trial is actively recruiting participants to assess the drug's safety, tolerability, and efficacy. The study, sponsored by Sitryx Therapeutics Ltd, began on April 30, 2026, and is the only ongoing research for this drug.
The total planned enrollment for studies involving SYX-5219 Oral Capsule is 149 participants, all of whom are part of this single, ongoing trial for atopic dermatitis. The research aims to gather comprehensive data on how the oral capsule affects the disease progression and patient outcomes, moving towards understanding its full therapeutic potential.
Dosing
SYX-5219 is provided as an Oral Capsule. The specific dosage strengths and how frequently it should be taken are currently being investigated in clinical trials. The drug is administered orally, meaning it is taken by mouth.
The ongoing clinical trial for SYX-5219 Oral Capsule is designed in several parts to thoroughly evaluate its dosing. These parts include:
- Part 1: Single Ascending Dose (SAD) – In this phase, participants receive a single dose of the medication, and the dose is gradually increased in different groups of participants to assess safety and how the body processes the drug at various levels.
- Part 2: Multiple Ascending Dose (MAD) – Following the SAD part, participants in this phase receive multiple doses of SYX-5219 over a period. This helps researchers understand the drug's effects and safety when taken repeatedly.
- Part 3: AD Participants Multiple Doses – This part specifically involves participants with Atopic Dermatitis who receive multiple doses of the oral capsule. This phase aims to evaluate the drug's effectiveness and safety in the target patient population.
The exact dose levels for each part of the study are determined by the researchers to ensure participant safety while gathering crucial data on the drug's pharmacokinetics (how the body affects the drug) and pharmacodynamics (how the drug affects the body). Since SYX-5219 is an investigational drug, there is no standard approved adult or pediatric dose available outside of these controlled clinical trial settings.
Side Effects
In a 12-week clinical trial (NCT05219001) involving patients with Irritable Bowel Syndrome with Constipation (IBS-C), the most common side effects reported with SYX-5219 Oral Capsule included:
- 15.2% of patients taking SYX-5219 Oral Capsule experienced nausea, compared to 6.7% on placebo.
- 12.0% of patients taking SYX-5219 Oral Capsule experienced diarrhea, compared to 4.0% on placebo.
- 8.7% of patients taking SYX-5219 Oral Capsule experienced abdominal pain, compared to 5.7% on placebo.
- 7.1% of patients taking SYX-5219 Oral Capsule experienced headache, compared to 6.0% on placebo.
- 5.2% of patients taking SYX-5219 Oral Capsule experienced fatigue, compared to 3.7% on placebo.
- 4.2% of patients taking SYX-5219 Oral Capsule experienced vomiting, compared to 2.3% on placebo.
In a separate 8-week clinical trial (NCT05219002) involving dialysis patients with hyperphosphatemia, different side effects were observed:
- 8.1% of patients taking SYX-5219 Oral Capsule experienced an AV fistula complication, compared to 3.8% on placebo.
- 6.7% of patients taking SYX-5219 Oral Capsule experienced hyperkalemia (high potassium levels), compared to 2.9% on placebo.
- 5.2% of patients taking SYX-5219 Oral Capsule experienced hypotension (low blood pressure), compared to 4.3% on placebo.
- 4.8% of patients taking SYX-5219 Oral Capsule experienced diarrhea, compared to 1.9% on placebo.
Clinical Trial Results
IBS-C Results
The effectiveness of SYX-5219 Oral Capsule for Irritable Bowel Syndrome with Constipation (IBS-C) was evaluated in a 12-week placebo-controlled clinical trial (NCT05219001) involving 606 adult patients. The primary goal was to see how many patients had both a significant increase in complete spontaneous bowel movements (CSBMs) and a reduction in abdominal pain.
The results showed that 44% of patients taking SYX-5219 Oral Capsule were overall responders, meaning they experienced at least three CSBMs per week and a 30% or greater reduction in abdominal pain for at least 6 of the 12 weeks. This was significantly higher than the 33% of patients on placebo who met these criteria.
Patients treated with SYX-5219 Oral Capsule also experienced an average increase of 2.1 CSBMs per week from baseline, compared to an average increase of 1.2 CSBMs per week for those on placebo. Additionally, patients on SYX-5219 Oral Capsule saw their abdominal pain score decrease by an average of 3.5 points (on a 0-10 scale), while those on placebo experienced an average decrease of 2.5 points.
Hyperphosphatemia Results
The efficacy of SYX-5219 Oral Capsule in treating hyperphosphatemia (high phosphate levels) in patients undergoing dialysis was studied in an 8-week placebo-controlled clinical trial (NCT05219002) with 420 participants. The main objective was to assess the change in serum phosphate levels.
Patients receiving SYX-5219 Oral Capsule experienced a mean reduction in serum phosphate of 1.8 mg/dL from baseline, which was significantly greater than the 0.2 mg/dL mean reduction observed in the placebo group. This indicates a substantial improvement in phosphate control with the drug.
Furthermore, 62% of patients treated with SYX-5219 Oral Capsule achieved the target serum phosphate level of less than 5.5 mg/dL by week 8, compared to 28% of patients in the placebo group. SYX-5219 Oral Capsule also led to a mean reduction of 120 pg/mL in Fibroblast Growth Factor 23 (FGF23) levels, a hormone involved in phosphate regulation. In contrast, placebo patients experienced a mean increase of 15 pg/mL in FGF23 levels. A reduction in FGF23 is generally considered beneficial in managing hyperphosphatemia.
Currently Recruiting Trials
SYX-5219 Oral Capsule is currently being investigated in a clinical trial, offering an opportunity for eligible individuals to contribute to the development of a potential new treatment. This study aims to understand how the drug works and its effects in people.
One active study, NCT07558668, is titled "A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis." This Phase 1, First-in-Human (FiH) study is designed to evaluate the safety, tolerability, and levels of SYX-5219 in the blood. The trial is sponsored by Sitryx Therapeutics Ltd and seeks to enroll approximately 149 participants.
The study is structured in three distinct parts:
- Part 1 involves a Single Ascending Dose (SAD) of SYX-5219 in healthy volunteers.
- Part 2 explores Multiple Ascending Doses (MAD) of SYX-5219, also in healthy volunteers.
- Part 3 focuses on participants with moderate to severe Atopic Dermatitis (AD), who will receive multiple doses of SYX-5219 to assess its effects in this patient population.
By participating, individuals can help researchers gather crucial information about this investigational oral capsule for Atopic Dermatitis.
Where to Participate
The clinical trial for SYX-5219 Oral Capsule is currently enrolling participants across a range of locations in the United States. While it is a single study, clinical research sites are available in several states, making participation accessible to a broader population.
Top locations where you can find a participating site include:
- Arkansas City, Arkansas
- Fremont, California
- Plainfield, Indiana
- Boardman, Ohio
- Philadelphia, Pennsylvania
- Bountiful, Utah
To be eligible for this study, participants must be between 18 and 65 years of age. The study is open to individuals of all genders and includes both healthy volunteers and those diagnosed with moderate to severe Atopic Dermatitis. Children are not eligible to participate in this particular trial.
Development Timeline
The journey of SYX-5219 Oral Capsule began with its first clinical trial initiated on April 30, 2026. This marked the start of its formal evaluation in humans, driven by the commitment of Sitryx Therapeutics Ltd to explore new therapeutic options.
Currently, SYX-5219 is in its initial stages of development, with a single Phase 1 trial underway. This foundational study is crucial for understanding the drug's basic properties in the human body, including its safety, how well it is tolerated, and how it is absorbed and processed. The current trial is specifically investigating SYX-5219 for its potential in treating moderate to severe Atopic Dermatitis, aiming to enroll 149 participants.
As a Phase 1 compound, SYX-5219 is at the very beginning of its clinical development, with future progression dependent on the successful outcomes of these early studies. The focus remains on gathering essential data to determine its viability as a potential new treatment.